Investor Presentation Full Year 2021
14
Investor presentation
Full year 2021
Novo NordiskⓇ
R&D milestones for Q4 2021 and through 2022
Project
OzempicⓇ 2.0 mg
Q4 2021
EU decision
Diabetes care
FDC Sema OW GIP
-
Phase 2 initiation
Cagrisema T2DM
Clinical milestones¹
H1 2022
US decision
Phase 1 results
Regulatory milestones¹
H2 2022
Phase 2 results
RybelsusⓇ
IcoSema
CN submission
Phase 3 initiation
PDS290 variant: EU decision
Phase 3 initiation
Phase 1 results
Icodec
Ideal Pump Insulin
Obesity care
WegovyⓇ
Phase 3a results
Phase 1 results
EU decision
CagriSema
LA-GDF15
Biopharm
Sogroya® (somapacitan)
✓ Phase 3 results (GHD)
US/EU submission (GHD)
Mim8
Phase 1/2 results²
Concizumab
Eclipse/NDec
Nedosiran (PH)5
Other serious chronic diseases
PRX004 (ATTR-CM)
Phase 3a results (HWI)4
Phase 2 initiation
US submission
Phase 2 initiation
1
Expected to be published in the given quarter or in the subsequent quarterly company announcement. 2 First cohorts successfully completed. 3 First patient first in Q4 2021, which is solely for baselining purposes
4 Results for haemophilia A and B expected in H2 2022. 5 Primary hyperoxaluria
Note: Trial initiations could be impacted by COVID-19; GHD: Growth Hormone Deficiency; sema: semaglutide; HwI: Haemophilia with inhibitors; ATTR-CM: Transthyretin Amyloid Cardiomyopathy
Phase 3 treatment³
US/JP submission (HwI)View entire presentation